Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

NCT00379912 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped Insufficient response rate

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Azacitidine
DRUG: Erythropoietin
DRUG: Azacitidine (Monotherapy)

Sponsor

Larry Cripe, MD

Collaborators

[object Object]
[object Object]
[object Object]